uniQure Announces Closing of Sale of Manufacturing Facility to Genezen
23 7월 2024 - 8:05PM
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company
advancing transformative therapies for patients with severe medical
needs, today announced the closing of the sale of its global
manufacturing facility in Lexington, Massachusetts to Genezen, a
leading contract development and manufacturing organization
specializing in the supply of retroviral vectors, lentiviral
vectors, and adeno-associated virus (AAV) technologies.
“With the completion of the divestiture, we take
an important step toward achieving our goal of significantly
reducing expenses and streamlining operations,” stated Matt
Kapusta, chief executive officer of uniQure. “Additionally, this
transaction provides uniQure continued and preferred access to
world-class gene therapy manufacturing capabilities to advance our
gene therapy product candidates and enables us to focus our future
investments on projects that have the potential to meaningfully
increase shareholder value. We remain committed to identifying
further cost reduction opportunities and anticipate announcing
additional progress later this quarter.”
uniQure and Genezen expect a seamless
transition, with nearly all employees who were offered employment
successfully joining Genezen. As a result of the transaction,
uniQure becomes a meaningful shareholder of Genezen and Mr. Kapusta
has joined Genezen’s Board of Directors. uniQure expects immediate
reductions in future recurring cash burn of approximately $40
million per year, which includes interest expense savings from the
retirement of $50 million in outstanding debt.
With the transaction now complete, Amin Abujoub,
Ph.D. who currently serves as Chief Quality Officer has been
appointed to the new role of Chief Technical Operations Officer and
will be responsible for global oversight of contract manufacturers,
including Genezen, as well as internal operations, facilities,
process and analytical development, and quality. As a result of the
divestiture, the Chief Operating Officer role was eliminated, and
Pierre Caloz will depart the company, continuing to lend his
expertise in an advisory capacity.
“I want to express my heartfelt gratitude to
Pierre for his years of leadership, dedication and significant
contributions to the company, all of which were instrumental in
establishing uniQure’s industry-leading commercial manufacturing
capabilities and achieving multiple regulatory approvals for
HEMGENIX®,” added Matt Kapusta. “I also look forward to working
with Amin in his new role and am highly confident that he will
continue to have significant impact on our mission of delivering
transformational gene therapies to patients in need.”
About Genezen
Genezen is a contract development and manufacturing
organization(“CDMO”) with preclinical to commercial capabilities
across retroviral vectors, lentiviral vectors, and AAV. Genezen
operates a preclinical and early phase GMP site in Indianapolis, IN
and a state of the art, commercially approved gene therapy
manufacturing site in Lexington, MA. Led by an extremely
experienced team, a science-first approach influences continual
investment in scalable, high-yield manufacturing processes and
best-in-class technologies. For more information about Genezen,
please visit genezen.com.
About uniQure
uniQure is delivering on the promise of gene
therapy – single treatments with potentially curative results. The
approvals of uniQure’s gene therapy for hemophilia B – an historic
achievement based on more than a decade of research and clinical
development – represent a major milestone in the field of genomic
medicine and ushers in a new treatment approach for patients living
with hemophilia. uniQure is now advancing a pipeline of proprietary
gene therapies for the treatment of patients with Huntington's
disease, refractory temporal lobe epilepsy, ALS, Fabry disease, and
other severe diseases. www.uniQure.com
uniQure Forward-Looking
Statements
This press release contains forward-looking
statements. All statements other than statements of historical fact
are forward-looking statements, which are often indicated by terms
such as "anticipate," "believe," "could," “establish,” "estimate,"
"expect," "goal," "intend," "look forward to", "may," "plan,"
"potential," "predict," "project," “seek,” "should," "will,"
"would" and similar expressions. Forward-looking statements are
based on management's beliefs and assumptions and on information
available to management only as of the date of this press release.
Examples of these forward-looking statements include, but are not
limited to, statements concerning the availability of manufacturing
resources and capacity for the Company’s gene therapy pipeline; the
potential for future projects and their ability to increase
shareholder value; expectations regarding the transition of the
Company’s former employees to Genezen; the Company’s expectations
that the transaction will reduce operating expenses and cash burn
by approximately $40 million per year; and the Company’s ongoing
review of operations and options to reduce expenses and
expectations regarding the timeline for completion and announcement
thereof and whether such review will be successful in reducing
operation expenses and increasing shareholder value. The Company’s
actual results could differ materially from those anticipated in
these forward-looking statements for many reasons. These risks and
uncertainties include, among others: (i) the institution or outcome
of any legal proceedings that may be instituted against the Company
or Genezen following the transaction; (ii) the risk that the
proposed transaction disrupts current plans and operations as a
result of the announcement and consummation of the proposed
transaction; (iii) the ability to recognize the anticipated
benefits of the proposed transaction, included preferred access to
manufacturing resources for the Company’s gene therapy pipeline;
(iv) changes in applicable laws or regulations; (v) costs related
to the transaction; (vi) the possibility that the Company may be
adversely affected by other economic, business and/or competitive
factors; (vii) risks associated with the clinical results and the
development and timing of the Company’s programs; (viii) the
Company’s interactions with regulatory authorities, which may
affect the initiation, timing and progress of clinical trials and
pathways to approval; (ix) the Company’s ability to continue to
build and maintain the company infrastructure and personnel needed
to achieve its goals; (x) the continued development and acceptance
of gene therapies; (xi) the Company’s ability to fund its
operations and to raise additional capital as needed; and (xii) the
impact of global economic uncertainty, rising inflation, rising
interest rates or market disruptions on its business. These risks
and uncertainties are more fully described under the heading "Risk
Factors" in the Company’s periodic filings with the U.S. Securities
& Exchange Commission (“SEC”), including its Annual Report on
Form 10-K filed February 28, 2024 and in other filings that the
Company makes with the SEC from time to time. Given these risks,
uncertainties and other factors, you should not place undue
reliance on these forward-looking statements, and the Company
assumes no obligation to update these forward-looking statements,
even if new information becomes available in the future.
uniQure Contacts: |
|
|
|
FOR INVESTORS: |
FOR MEDIA: |
|
|
Chiara Russo |
Tom Malone |
Direct: 617-306-9137 |
Direct: 339-970-7558 |
Mobile: 617-306-9137 |
Mobile:339-223-8541 |
c.russo@uniQure.com |
t.malone@uniQure.com |
uniQure NV (NASDAQ:QURE)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024
uniQure NV (NASDAQ:QURE)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024